Mitchell E Blatt, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1210 County Road E W, Arden Hills, MN 55112 Phone: 651-523-8400 Fax: 651-484-9650 |
Todd W Gothard, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1210 County Road E W, Arden Hills, MN 55112 Phone: 651-523-8400 Fax: 651-484-9650 |
Lauren B Baker, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1210 County Road E W, Arden Hills, MN 55112 Phone: 651-523-8400 Fax: 651-484-9650 |
News Archive
The Associated Press/The Boston Herald: "Workers who better understand their health insurance plans — from their share of premiums to co-payments for doctor office and emergency room visits — are more likely to make more cost-efficient decisions, a new study finds. The study, which surveyed about 1,500 government workers in Massachusetts," was published in The American Journal of Managed Care.
A new study published in the journal Neuron on October 9, 2019 reports that scientists have unlocked part of the secrets of the SETD1A gene – how mutations in the gene put the individual at risk for the condition.
Oncotarget published "The presence of polymorphisms in genes controlling neurotransmitter metabolism and disease prognosis in patients with prostate cancer: a possible link with schizophrenia" reported that polymorphisms of neurotransmitter metabolism genes were studied in patients with prostate cancer (PC) characterized by either reduced or extended serum prostate-specific antigen doubling time corresponding to unfavorable and favorable disease prognosis respectively.
Brain imaging scans may one day provide useful information on the response to psychotherapy in patients with depression or anxiety, according to a review of current research in the November/December issue of the Harvard Review of Psychiatry, published by Wolters Kluwer.
Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).
› Verified 8 days ago